Factor XI (FXI), the zymogen of activated FXI (FXIa), is an attractive target for novel anticoagulants because FXI inhibition offers the potential to reduce thrombosis risk while minimizing the risk of bleeding. BAY 1213790, a novel anti-FXIa antibody, was generated using phage display technology. Crystal structure analysis of the FXIa-BAY 1213790 complex demonstrated that the tyrosine-rich complementarity-determining region 3 loop of the heavy chain of BAY 1213790 penetrated deepest into the FXIa binding epitope, forming a network of favorable interactions including a direct hydrogen bond from Tyr102 to the Gln451 sidechain (2.9 Å). The newly discovered binding epitope caused a structural rearrangement of the FXIa active site, revealing a novel allosteric mechanism of FXIa inhibition by BAY 1213790. BAY 1213790 specifically inhibited FXIa with a binding affinity of 2.4 nM, and in human plasma, prolonged activated partial thromboplastin time and inhibited thrombin generation in a concentration-dependent manner.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jmb.2019.09.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Systematic Review of Safety and Efficacy of Factor XI/XIa Inhibitors in Patients With ESKD on Hemodialysis.
Kidney Int Rep
January 2025
Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Introduction: Factor XI/XIa (FXI/XIa) has emerged as a potential target for antithrombotic therapy, driven by preclinical evidence showing the role of FXI/XIa inhibition for preventing thrombosis without impeding hemostasis. This is particularly promising for patients at high risk of both thromboembolic events and bleeding, such as patients with end-stage kidney disease (ESKD) on hemodialysis (HD).
Methods: We systematically searched Embase, MEDLINE, and ClinicalTrials.
From the INVICTUS Trial to Current Considerations: It's Not Time to Retire Vitamin K Inhibitors Yet!
Pharmaceuticals (Basel)
October 2024
Division of Cardiology and CardioLab, Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Article Synopsis
- Atrial fibrillation (AF) is common and usually treated with oral anticoagulants to prevent strokes, where direct oral anticoagulants (DOAC) are more effective in reducing certain types of bleeding compared to vitamin K antagonists (VKA).
- The INVICTUS study showed that the DOAC rivaroxaban was not superior to VKA in preventing serious complications like stroke for patients with rheumatic valvular AF, leading to higher death and drug discontinuation rates in the DOAC group.
- While VKAs remain the standard treatment for patients with moderate-to-severe mitral stenosis and prosthetic valves, new factor XI inhibitors show promise in reducing bleeding risks and are currently undergoing further testing in AF and
Pharmacokinetics and pharmacodynamics of the factor XIa-inhibiting antibody osocimab in healthy male East Asian volunteers: Results from two phase 1 studies.
Pharmacol Res Perspect
October 2024
Clinical Statistics & Analytics China, Bayer Healthcare Company Ltd, Beijing, China.
The pharmacokinetics, pharmacodynamics, immunogenicity, and safety of osocimab single doses in healthy Chinese and Japanese volunteers over 149 days were evaluated. Two phase 1 single-blinded, placebo-controlled studies with 27 Japanese and 50 Chinese participants were conducted. Osocimab was investigated with IV doses of 0.
View Article and Find Full Text PDFTherapeutic Potential of FXI Inhibitors: Hype or Hope?
Drugs
September 2024
Division of Cardiology, University of Florida College of Medicine-Jacksonville, 655 West 8th Street, Jacksonville, FL, 32209, USA.
Article Synopsis
- In the past 20 years, new blood thinners called direct oral anticoagulants (DOACs) have been developed, making treatment safer and easier for patients.
- However, DOACs can't be used in every situation, and there's still a concern about bleeding risks.
- Researchers are now looking at a new type of blood thinner that targets the intrinsic pathway (factor XI inhibitors) to better separate normal blood clotting from harmful blood clots, but some recent trials have had mixed results and one important study was stopped early.
Drug-Drug Interactions of FXI Inhibitors: Clinical Relevance.
Hematol Rep
March 2024
Coordinating Research Centre on Pharmacological Interactions, University of Milan, 20133 Milan, Italy.
Inhibitors of the factor FXI represent a new class of anticoagulant agents that are facing clinical approval for the treatment of acute coronary syndrome (ACS), venous thromboembolism (VTE), and stroke prevention of atrial fibrillation (AF). These new inhibitors include chemical small molecules (asundexian and milvexian), monoclonal antibodies (abelacimab, osocimab, and xisomab), and antisense oligonucleotides (IONIS-FXIRX and fesomersen), and thus, they have very peculiar and different pharmacokinetic and pharmacodynamic properties. Besides their clinical efficacy and safety, based on their pharmacological heterogeneity, the use of these drugs in patients with comorbidities may undergo drug-drug interactions (DDIs) with other concomitant therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!